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Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against
the many diseases caused by vector-borne pathogens. We tested the ability of an anti-tick vaccine derived from a tick
cement protein (64TRP) of Rhipicephalus appendiculatus to protect mice against tick-borne encephalitis virus (TBEV)
transmitted by infected Ixodes ricinus ticks. The vaccine has a ‘‘dual action’’ in immunized animals: when infested with
ticks, the inflammatory and immune responses first disrupt the skin feeding site, resulting in impaired blood feeding,
and then specific anti-64TRP antibodies cross-react with midgut antigenic epitopes, causing rupture of the tick midgut
and death of engorged ticks. Three parameters were measured: ‘‘transmission,’’ number of uninfected nymphal ticks
that became infected when cofeeding with an infected adult female tick; ‘‘support,’’ number of mice supporting virus
transmission from the infected tick to cofeeding uninfected nymphs; and ‘‘survival,’’ number of mice that survived
infection by tick bite and subsequent challenge by intraperitoneal inoculation of a lethal dose of TBEV. We show that
one dose of the 64TRP vaccine protects mice against lethal challenge by infected ticks; control animals developed a
fatal viral encephalitis. The protective effect of the 64TRP vaccine was comparable to that of a single dose of a
commercial TBEV vaccine, while the transmission-blocking effect of 64TRP was better than that of the antiviral vaccine
in reducing the number of animals supporting virus transmission. By contrast, the commercial antitick vaccine
(TickGARD) that targets only the tick’s midgut showed transmission-blocking activity but was not protective. The
64TRP vaccine demonstrates the potential to control vector-borne disease by interfering with pathogen transmission,
apparently by mediating a local cutaneous inflammatory immune response at the tick-feeding site.
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Introduction
Blood-feeding parasites act as vectors of an enormous
range of pathogens that cause diseases in humans and other
animals. For example, a single tick species (Ixodes ricinus) can
transmit viruses, bacteria, and protozoa that cause tick-borne
encephalitis, Lyme disease, and babesiosis. Protection by
immunization requires several different antipathogen vac-
cines, while vector control generally relies on the use of
repellents, or on large-scale, repeated applications of
pesticides that raise issues concerning pesticide resistance,
food residues, health risks, and environmental pollution. New
strategies are required to control both the vectors and
pathogens they transmit.
A novel approach is antivector vaccines designed to target
the vector in such a way that they protect against pathogens
transmitted by the vector. Several observations suggest this
may be feasible. Reduced transmission capacity of ticks fed on
tick-immune animals [1–5] and humans [6] has been reported
for several tick-borne pathogens, although not all [7]. For
example, people who express an immune reaction against the
vector tick Ixodes scapularis appear to acquire Lyme disease
less frequently than those who experience no such immune
response [6]. For insect vectors, bites of uninfected sand flies
provide protection of mice against cutaneous leishmaniasis
[8], and seroconversion of humans against sandfly vectors
correlates with development of protective immunity to
leishmaniasis [9]. Experimentally, it has been shown that
antibodies raised against mosquito midgut lysates lowered
vector competence, reducing transmission of human malarial
parasites [10], while antibodies to a sandfly midgut galectin
eliminated sandfly transmissible infections of leishmania [11]
in membrane feeding studies.
Arthropod vectors induce immunosuppression in the host
during feeding and secrete pathogen transmission-enhancing
factors that counteract host rejection responses [12–15]. For
example, the Lyme disease agent Borrelia burgdorferi appears to
exploit tick salivary proteins (BIP and Salp15 from I. ricinus and
I. scapularis, respectively) to facilitate transmission to the
mammalian host [16,17]. Therefore research on antivector
immunity needs to be refined to distinguish antigens that
induce protective immune responses whilst preventing patho-
gen transmission. Immunization with SP15 plasmid vaccine,
targeting a 15-kDa saliva protein of the sand fly vector,
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Phlebotomus papatasi, induced humoral and delayed type
hypersensitivity responses that successfully controlled Leish-
mania major infection in mice [18]. Immunity against the sand
fly salivary antigen modified the dermal site of infection,
limiting leishmania parasite replication although not appar-
ently blocking transmission. Recombinant forms of a 15-kDa
tick saliva protein (64TRPs) of Rhipicephalus appendiculatus
likewise induce potent humoral and delayed type hyper-
sensitivity responses [19]. In hamster, guinea pig, and rabbit
models, this cement antigen acts as a dual-action vaccine by
targeting the tick-feeding site (impairing attachment and
feeding) and cross-reacting with ‘‘concealed’’ midgut antigens,
resulting in death of engorged ticks [19,20]. The protein is
derived from the cement cone that secures the tick’s mouth-
parts in the host skin and, as a broad-spectrum vaccine antigen,
is effective against adult and immature stages of several tick
species, including I. ricinus [20]. In this study, we tested the
potential of the 64TRP anti-tick vaccine to protect mice
against a lethal infection of tick-borne encephalitis virus (TBEV)
transmitted by its natural vector, I. ricinus. In humans, TBEV is
the most important vector-borne virus infection in Europe
and northern Asia [21]. Both transmission-blocking and
protective activities were demonstrated by the 64TRP vaccine.
Comparison of the results with those obtained whenmice were
immunized with either the commercial TBEV vaccine or the
commercial anti-tick vaccine (TickGARD), together with
histological and immunocytological studies, indicate that the
key mode of action of 64TRP immunisation is the local
cutaneous delayed type hypersensitivity response (possibly a
CD8þ phenotype) evoked at the skin site of tick feeding.
Results
Effect of Immunizations on TBEV Transmission and Disease
Evaluation of the transmission-blocking and protective
effects of immunization with either 64TRP tick cement
antigens, TBEV virus, or TickGARD was based on comparing
three parameters against controls: (1) ‘‘transmission’’—virus
transmission measured by the number of uninfected nymphal
ticks that became infected when cofeeding with a single
infected adult female; (2) ‘‘support’’—number of mice
supporting transmission from infected to uninfected ticks
(this involves virus replication in mouse tissues) [22]; and (3)
‘‘survival’’—number of mice that survived exposure to
infected ticks (Figure 1). To ensure that surviving animals
had been exposed to an infected tick bite, they were
challenged by intraperitoneal (i.p.) inoculation of a lethal
Figure 1. Effect of Immunization on Mice Infested with Virus-Infected
and -Uninfected Ticks
Comparison of immunization with either 64TRP antigens, a commercial
TBEV vaccine, or the commercial anti-tick vaccine (TickGARD) on (A)
transmission ¼ % uninfected nymphal ticks that became infected; (B)
support¼ % mice supporting cofeeding virus transmission between an
infected adult female tick and uninfected nymphs; and (C) survival¼ %
mice that survived an infected tick bite (only animals surviving subsequent
i.p. inoculation with 1,000 PFU TBEV were included in the analyses).
DOI: 10.1371/journal.ppat.0020027.g001
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Synopsis
Blood-sucking vectors such as mosquitoes and ticks transmit
hundreds of micro-organisms that cause diseases like malaria and
Lyme disease. Controlling so many diseases is an enormous
challenge. A new idea is to make vaccines against the vectors
rather than against all the individual disease agents they carry. The
authors examined this hypothesis using a vaccine prepared from
tick cement. This cement is secreted by ticks to help them attach to
a human or animal to feed. A mouse model was used in which mice
were infested with ticks infected with tick-borne encephalitis virus
(TBEV), the most important vector-borne virus in Europe and
northern Asia. The control mice developed fatal encephalitis and
died about a week after being bitten by the infected tick. By
contrast, the tick cement vaccine gave protection similar to the level
seen in mice immunized with a single shot of the commercial TBEV
vaccine for humans. However, a commercial tick vaccine used to
control cattle ticks did not protect the mice. The authors’ tick
cement vaccine appeared to work by causing a cellular immune
response in the skin where ticks were feeding. These results show
that it is feasible to produce a vaccine against a tick that protects
against the disease agent it transmits.
dose of TBEV. Animals that did not survive i.p. inoculation
and did not yield infected ticks were excluded from the
analyses (see Materials and Methods, ‘‘Data analysis’’). Overall
there was a correlation between ‘‘survival’’ and ‘‘support,’’ but
not between ‘‘survival’’ and ‘‘transmission’’: mice that
supported virus transmission were significantly less likely to
survive (r ¼ 0.557, p ¼ 0.02), whereas there was no
correspondence between the % nymphs infected and the %
mice that survived (r ¼0.180, p ¼ 0.488).
Controls. All the unimmunized mice supported virus
transmission, with each animal yielding at least three infected
nymphs (Table 1). Hence TBEV had been transmitted from
the infected female tick to the mouse on which it was feeding,
and then transmitted from the infected mouse to uninfected
cofeeding nymphs. Similar results were obtained with control
mice immunized with glutathione S-transferase (GST). Most
of the control mice died within 9–11 d of exposure to a
TBEV-infected tick. There was no evidence of an anti-tick
effect: the % nymphs fed on control animals compared with
the treated groups were similar. However, the experiments
were not designed to assess the effect of 64TRP immunization
on tick feeding and tick survival, as demonstrated previously
[19,20]. Thus nymphal ticks were removed prior to repletion
and drop-off (for virus detection) instead of being assessed
for feeding success and survival.
Effect of 64TRP immunizations. Transmission-blocking
activity was observed for 64TRP-immunized mice. Signifi-
cantly fewer animals supported virus transmission to nymphs
(v2 ¼ 39.2, df ¼ 3, p  0.001) and fewer nymphs became
infected (v2 ¼ 46.1, df ¼ 1, p , 0.001) compared with the
controls (Figure 1B and 1A, respectively). In addition, 64TRP
immunization provided protection against a fatal infection
with TBEV. Significantly more 64TRP-immunized mice
survived compared with the controls (v2 ¼ 225, df ¼ 1, p ,
0.001) (Figure 1C). The highest level of protection from a
single 64TRP dose was observed with TRP6 (Table 1).
Immunization with the 64TRP cocktails, including two
64TRP doses (Table 2, group I), gave results that were not
significantly different from the single immunogens (Table 1,
group I).
Effect of TBEV vaccine. The virus vaccine was similar to
64TRP in reducing the level of virus transmission to
cofeeding ticks (Figure 1A). However, whereas significantly
fewer 64TRP-immunized mice supported virus transmission
compared with the controls, this was not the case for mice
immunized with the virus vaccine (v2¼ 5.83, df¼ 7, p¼ 0.735)
(Figure 1B). The protective effect of immunization with a
single dose of the 64TRP tick antigens did not differ
significantly from a single dose of the TBEV vaccine (v2 ¼
5.83, df ¼ 7, p , 0.560) (Figure 1C).
Effect of TickGARD vaccine. Immunization with the
commercial TickGARD vaccine (Table 2) provided trans-
mission blocking similar to that observed following 64TRP-
immunization (v2 ¼ 10.5, df ¼ 7, p , 0.162). Compared with
the controls, both TickGARD and 64TRP treatments gave
lower transmission (v2 ¼ 32.1 df ¼ 1, p ¼, 0.001), and fewer
mice supported transmission (v2 ¼ 27.2, df ¼ 2, p ¼ , 0.001)
(Figure 1A and 1B, respectively). However, there was a
significant difference in protective effect of the tick
cement–derived vaccine (64TRP) compared with the tick
midgut vaccine (TickGARD) (v2 ¼ 52.2, df ¼ 15, p , 0.001).
Unlike 64TRP, TickGARD did not protect mice against a fatal
infection with TBEV (Figure 1C), even when the animals were
immunized with three doses of the commercial tick vaccine
(Table 1, group L).
Cellular and Humoral Immune Responses
A protective anti-tick immune response that blocks tick-
borne pathogen transmission is associated with development
of tick-specific antibodies [23,24] and cellular infiltration
[25,26]. Therefore, we compared the responses of 64TRP-
immunized mice with those of controls to identify a possible
immunological basis for the observed transmission-blocking
and protective effects. Differential humoral and cellular
Table 1. Evaluation of the 64TRP Anti-Tick Vaccine in Protecting Mice against Transmission of a Lethal TBEV Infection by Its Natural
Vector, I. ricinus, and Comparison with Commercial Antiviral (FSME-IMMUN) and Anti-Tick (TickGARD) Vaccines
Group of Mice Treatment Transmission: Number
of Nymphs Infected/
Number Fed (%)
Support: Number of Mice
Supporting Transmission/
Total Number Challenged
by Infected Tick (%)
Survival: Number of
Mice Survived/Total
Number Challenged
by Infected Ticks (%)a
Trial I Trial II Trial I Trial II Trial I Trial II
Controls A. GST 25/66 (38%) 42/87 (48%) 7/9 (78%) 10/10 (100%) 1/9 (11%) 2/10 (20%)
B. Unimmunized 58/90 (64%) 36/71 (51%) 10/10 (100%) 10/10 (100%) 3/10 (30%) 0/10 (0%)
TRP-immunized C. TRP2 15/57 (26%) 7/87 (8%) 6/7 (86%) 4/9 (44%) 3/7 (43%) 3/9 (33%)
D. TRP5 6/86 (7%) 10/87 (11%) 2/9 (22%) 4/10 (40%) 4/9 (44%) 6/10 (60%)
E. TRP6 24/73 (33%) 5/62 (8%) 4/7 (57%) 3/7 (43%) 5/7 (71%) 5/7 (71%)
F. TRP2 þ TRP5 14/84 (17%) ND 4/9 (44%) ND 2/9 (22%) ND
G. TRP2 þ TRP6 20/89 (22%) ND 6/9 (67%) ND 1/9 (11%) ND
H. TRP5 þ TRP6 15/77 (19%) ND 5/9 (56%) ND 3/9 (33%) ND
I. TRP5 & TRP6 ND 3/63 (5%) ND 2/8 (25%) ND 7/8 (87%)
Antivirus vaccine J. TBEV vaccine ND 38/180 (21%) ND 12/17 (71%) ND 15/17 (88%)
Anti-tick vaccine K. TickGARD, 1 dose ND 23/89 (26%) ND 5/12 (42%) ND 2/12 (17%)
L. TickGARD, 3 doses ND 8/106 (7%) ND 4/11 (36%) ND 2/11 (18%)
aData shown only for mice that survived infected tick challenge and subsequent i.p. inoculation of a lethal dose of TBE.
ND, not done.
DOI: 10.1371/journal.ppat.0020027.t001
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responses were observed in 64TRP-immunized mice com-
pared with controls. Enzyme-linked immunosorbent assay
results showed that antibody titers to cognate 64TRPs in
64TRP-immunized mice increased 2- to 4-fold relative to
preinfestation titers (from a basal level of 1:4,000 to 1:8–
16,000), whereas antibodies to GST had fallen in GST-
immunized mice (to ,1:1,000) after infestation. TBEV anti-
body titers were not determined.
In response to tick infestation, marked cellular infiltration
was evident in skin sections of 64TRP-immunized animals. By
contrast, comparatively little cellular response to tick feeding
was observed in GST-immunized and unimmunized controls
(Figure 2). For example, TRP2 immunization showed pro-
nounced epidermal hyperplasia at the attachment site, with
characteristic epidermal cavities and intense leukocytic
infiltration in the dermis (Figure 2A), contrasting with the
control unimmunized (Figure 2B) and GST immunized
(Figure 2C) animals. The cement cone of I. ricinus showed
some leukocytes present (Figure 2A). In addition, skin
sections from TRP2 and TRP5 immunization revealed
perivascular cuffing, degranulating mast cells, numerous
lymphocytes, frequent macrophages, and some eosinophils,
dermal dendrocytes, neutrophils, and basophils (Figure 2D
and 2E). Fewer cells and cell types were observed in the GST
control, and they were mainly lymphocytes, macrophages,
and dermal dendrocytes (Figure 2F).
Evaluation of CD4þ and CD8þ T lymphocyte responses
revealed a CD8þ response in 64TRP-immunized mice
compared with GST and unimmunized animals (Figure 3).
For example, skin samples from the TRP5-immunized mice
showed a predominantly CD8þ T cell response, with
numerous T cells occluding several dermal blood vessels
(Figure 3C and 3D); a CD4þ T cell response was also observed
but to a lesser degree (Figure 3D). In contrast, the primary
response detected in the dermis of skin samples from control
unimmunized mice following tick infestation was a CD4þ T
cell response (Figure 3F) with a slight CD8þ effect. Control
samples from GST-immunized mice were negative for CD8þT
cells (Figure 3A), with a slight CD4þ T cell response (Figure
3B). The characteristic epidermal hyperplasia observed in the
histological profiles coincided with the site of tick attachment
(Figure 2A, which shows the cement cone). Attachment sites
were not observed in sections used for immunocytochemical
staining, which may explain the apparent absence of an
epidermal hyperplasia (Figure 3C and 3D).
Discussion
In the mouse model for tick-borne transmission of TBEV,
the virus is transmitted from an infected tick to the
uninfected mouse on which it feeds. The virus infects and
replicates in the skin site of feeding, and is then transmitted
from the infected mouse to uninfected ticks cofeeding on the
animal [23]. These transmission dynamics were observed for
the control unimmunized and GST-immunized mice. Of the
39 control mice, 95% supported virus transmission giving rise
to infected nymphs, and 51% uninfected nymphs feeding on
the control mice became infected. Only 15% of the mice
survived demonstrating the susceptibility of Balb/c mice to
TBEV infection.
By comparison with the controls, transmission-blocking
activity was observed in 64TRP-immunized mice. Only 48%
animals supported virus transmission to nymphs and fewer
nymphs became infected (16%) compared with the controls.
Remarkably, an average of 46% 64TRP-immunized mice
survived tick-transmitted virus infection and subsequent
lethal challenge by virus inoculation. The highest level of
protection from a single 64TRP dose was observed with TRP6
(71% survival). This construct shows the most extensive
antigenic cross-reactivity with whole nymphal extracts,
cement cone, and midgut of female I. ricinus [20]. 64TRP-
immunized mice developed antiviral protection even when
they did not support virus transmission to cofeeding nymphs.
For example, of the ten surviving TRP5-immunized mice,
eight animals did not yield infected nymphs, whereas all
surviving control mice produced infected nymphs. These data
indicate that the response of 64TRP-immunized mice to tick
feeding did not completely block virus transmission but
instead allowed sufficient exposure to the virus for the mouse
to develop protective immunity. Thus virus transmission
occurred from the infected female tick to the mouse, but not
from the mouse to uninfected cofeeding nymphs. The
experimental design did not allow us to distinguish immuni-
zation that completely blocked virus transmission from
infected ticks to mice, leaving the mice still susceptible to
infection. These animals would have been excluded from the
analyses because they would not have survived the subsequent
i.p. challenge with a lethal dose of TBEV.
The protective effect of immunization with a single dose of
the 64TRP tick antigens did not differ significantly from a
single shot of the commercially available inactivated TBEV
vaccine (FSME-IMMUN; Baxter, Vienna, Austria) most com-
monly used in Europe [21]. The virus vaccine was also similar
to the 64TRP vaccine in reducing the number of cofeeding
Table 2. Immunization Regimes
Mouse
Group
Treatment
Group
Treatment per Mouse
A Control 10 ll (10 lg) GST þ 90 ll PBS þ 100 ll TMG
B Control Unimmunized
C 64TRP 15 ll (10 lg) TRP2 þ 85 ll PBS þ 100 ll TMG
D 64TRP 20 ll (10 lg) TRP5 þ 80 ll PBS þ 100 ll TMG
E 64TRP 20 ll (10 lg) TRP6 þ 80 ll PBS þ 100 ll TMG
F 64TRP 20 ll (10 lg) TRP2 þ 25 ll (10 lg) TRP5 þ 55 ll PBS þ
100 ll TMG
G 64TRP 20 ll (10 lg) TRP2 þ 5 ll (10 lg) TRP6 þ 75 ll PBS þ
100 ll TMG
H 64TRP 25 ll (10 lg) TRP5 þ 5 ll (10 lg) TRP6 þ 70 ll PBS þ
100 ll TMG
I 64TRP Single dose of TRP5 (as group D) followed 3 wk later
by a single dose of TRP6 (as group E)
J TBEV vaccine 100 ll formaldehyde inactivated TBEV vaccine
(FSME-IMMUN; Baxter Hyland Immuno,
Vienna, Austria; prepared according to
manufacturer’s recommendations)
K TickGARD 100 ll 1:100 TickGARD Plus vaccine (25 ll/ml
glycosylated Bm86 tick antigen with VaxiMax in a
water-in-oil emulsion; Intervet Australia PTY Ltd.,
Bendigo East; dose according to manufacturer’s
recommendations)
L TickGARD Single dose of TickGARD (as in group K) followed by
two additional doses at 3-wk intervals
TMG, Titermaxgold adjuvant.
DOI: 10.1371/journal.ppat.0020027.t002
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ticks that acquired the infection. However, whereas signifi-
cantly fewer 64TRP-immunized mice supported virus trans-
mission compared with the controls, this was not the case for
mice immunized with the virus vaccine. Thus, under the
conditions used, the TBEV vaccine was not as effective as
64TRP in controlling transmission from the infected tick to
the immunized mouse and/or from the infected mouse to
uninfected cofeeding ticks. The results confirm a previous
study in which 89% natural rodent hosts immune to TBEV
supported cofeeding virus transmission [27], and indicate a
greater level of virus infection in virus-immune mice
compared with tick-immune mice. The contrasting results
also indicate a different mechanism of protection, which is
consistent with the lack of antigenic cross-reactivity between
64TRP antigens and TBEV proteins (unpublished data). The
TBEV vaccine is presumably controlling the infection in the
mouse, protecting the mouse against development of a fatal
encephalitis and reducing the number of nymphs that
become infected. By contrast, 64TRP appears to affect
transmission from the infected tick to the mouse, and from
the infected mouse to uninfected cofeeding nymphs, possibly
acting at the level of Langerhans cells, which play a role in
tick-borne TBEV transmission and are modulated by compo-
nent(s) in tick saliva [22,28].
Immunization with the commercial TickGARD vaccine
provided transmission-blocking similar to 64TRP-immuniza-
tion, with both significantly lower transmission rates to
nymphs and fewer mice supporting transmission compared
with controls. However, unlike 64TRP-immunization, the
transmission-blocking effects of TickGARD did not provide
protection against lethal infection with TBEV. TickGARD
and Gavac (the Cuban equivalent) are derived from Bm86, a
midgut antigen of unknown function [29]. These commercial
anti-tick vaccines induce an antibody-mediated response
targeted at midgut cells that results in rupture of the midgut,
tick mortality, and reduced reproductive output. They appear
to reduce the incidence of tick-borne diseases in cattle
(babesiosis and anaplasmosis) by depleting tick numbers [29].
The 64TRP antigen derived from a tick cement protein acts
in a similar way to the Bm86 antigen: 64TRP cross-reacts with
antigenic epitopes in the tick midgut, causing rupture to the
midgut resulting in mortality [19,20]. Although our exper-
imental design did not allow evaluation of the vaccination
effects on tick feeding/survival, the transmission-blocking
effects of TickGARD indicate that it affected the ability of
nymphs to acquire the infection. This is consistent with the
lack of correlation between the % nymphs infected and %
survivors. A previous study using 64TRP-immunized rabbits
and hamsters showed cross-protection against I. ricinus adults
and nymphs, causing increased mortality [20]. Thus, anti-tick
Figure 2. Skin Histological Response in Immunized Mice Infested with Virus-Infected and -Uninfected Ticks
Histological profiles of skin sections taken at d 4 of TBEV-infected I. ricinus tick challenge on Balb/c mice immunized with either TRP2 (A, D), TRP5 (E), or
GST (C, F), or unimmunized (B). Stained with hematoxylin and eosin (A–D) or ‘‘Hema Gurr’’ Rapid stain BDH (E, F) [19]. (A) (magnification 203) TRP2-
immunized animals, (B) (magnification 203) control unimmunized, and (C) (magnification 203) GST-immunized animals. Ep, epidermis; De, dermis; CC,
cement cone of I. ricinus. (D–E) (magnification 633) denote skin sections from TRP2 and TRP5 immunized mice, respectively, showing: perivascular
cuffing¼ yellow circle; degranulating mast cells¼ green arrow; numerous lymphocytes¼blue arrow; frequent macrophages¼ yellow arrow; and some
eosinophils¼white arrow; dermal dendrocytes¼ black arrow; neutrophils¼ gray arrow; and basophils¼ light blue arrow. (F) (magnification 633) skin
sections from GST control immunized mice showing lymphocytes, macrophages, and dermal dendrocytes.
DOI: 10.1371/journal.ppat.0020027.g002
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effects could increase the effectiveness of 64TRP as a
protective transmission-blocking vaccine by reducing the
tick vector population.
Mice immunized with 64TRP antigens reacted to tick
infestation with both humoral and cellular responses. The
increase in antibody titers in 64TRP-immunized mice relative
to preinfestation titers (not observed in GST-immunized
mice) indicates the secreted cement proteins of feeding ticks
elicited an anamnestic response. The differential humoral and
cellular responses of 64TRP-immunized mice compared with
controls were similar to those observed in guinea pigs, rabbits,
hamsters, and Boran cattle immunized with priming and
Figure 3. Skin Immunocytochemical Profile of Immunized Mice Infested with Virus-Infected and -Uninfected Ticks
Immunocytochemical profiles of skin sections taken at d 4 of TBEV-infected I. ricinus tick challenge on Balb/c mice immunized with either GST (A, B) or
TRP5 (C, D), or unimmunized (E, F), using rat anti-mouse CD4þ antiserum (B, D, and F) and rat anti-mouse CD8þ (A, C, and E) antiserum, with a negative
control sample (G, PBS plus normal rabbit serum). (C) TRP5-immunized mice: red arrowheads ¼ numerous CD8þ T cells; red circles ¼ CD8þ T cells
occluding the dermal blood vessels; and (D) yellow arrows¼CD4þ T cells. (E) and (F) unimmunized mice, few CD8þ T cells¼ red arrows and CD4þ T cells
¼ yellow arrows/yellow circle, respectively. (B) Control GST-immunized mice yellow arrows¼ few CD4þ T cells. (G) PBS-negative control skin sample¼no
T cells. Magnification 203.
DOI: 10.1371/journal.ppat.0020027.g003
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booster doses of 64TRP compared with GST preparations
([19,20] and unpublished data). These consistent responses of
64TRP-immunized animals to tick feeding show that natural
tick infestation stimulates anti-64TRP immunity, indicating
the potential of a 64TRP-based vaccine to provide long-lasting
immunity without the need for repeat vaccinations.
The humoral immune response observed is consistent with
the histological profile of marked epidermal hyperplasia and
infiltration of leukocytes following tick infestation of 64TRP-
immunized animals contrasting with comparatively little
cellular response to tick feeding in GST-immunized and
unimmunized controls. Furthermore, T and B lymphocytes,
plasma cells, macrophages, and dendritic cells are associated
with acquired immunity [30]. Interestingly, the 64TRP-
immunized mice demonstrated a predominantly CD8þ
response compared with controls. Previous studies show that
tick resistance is more effectively transferred with lymph
node cells than with only serum from tick-resistant animals
[31]. They imply an important role for cell-mediated
immunity and the need to determine T cell phenotype. Our
study is limited but the first to indicate the predominant
phenotype of the T cell response invoked by the 64TRP tick
cement antigen in a mouse model. A previous study reported
CD4þ cells outnumbering CD8þ cells in mice repeatedly
infested with I. ricinus nymphs that did not develop resistance
to tick infestation, indicating that a predominant CD4þ cell
type does not confer tick resistance in Balb/c mice [26]. Not
surprisingly, therefore, repeat tick infestation does not
induce full protection in laboratory mice [26]. By contrast,
in other host species (guinea pigs, rabbits, and cattle), innate
resistance to ticks is conserved during repeat tick infestations
[32]. Moreover, humans repeatedly infested with I. ricinus ticks
express dermal and perivascular infiltrates of CD8þ T
lymphocytes [25]. Thus the predominant CD8þ profile in
Balb/c mice immunized with 64TRP, and comparatively
insignificant CD4þ response, are consistent with previous
reports implicating the CD8þ phenotype in tick resistance.
Although it was not specifically determined, the observed
antivirus immunity is unlikely to be CD8 dependent. Protec-
tion against lethal TBEV infection is not T cell mediated but
has been linked to antibodies against a nonstructural virus
protein absent from the virion [33]. Other studies in C57BL6
mice indicate that activation of virus-specific memory B cells
to secrete IgG is independent of cognate or bystander T cell
help [34]. Induction of complement is the dominant mecha-
nism of protection, although when this pathway is inactivated
other mechanisms involving cytotoxic T lymphocytes and
natural killer cells come into play. T cells from immunized
mice are protective only in animals whose pre-existing
immune function had been impaired [35].
The marked cellular response to tick infestation in 64TRP-
immunized mice, contrasting with controls, indicates that the
immunomodulated site of tick feeding is disrupted. This
disruption would also counter the activity of saliva-activated
transmission factors present in I. ricinus saliva that promote
TBEV transmission [36]. The TBEV saliva-activated trans-
mission factor(s) has not been identified but appears to be
secreted after the tick cement proteins; hence, it is unlikely to
be the same molecule [27,37]. Thus, the observed protective
effects in 64TRP-immunized mice most likely result from
general humoral and cellular responses to tick feeding rather
than specific antiviral or anti–saliva-activated transmission
factor immunity. Our results indicate that TBEV transmitted
by infected ticks into the skin of 64TRP-immunized mice
enters a hostile microenvironment (e.g., Figure 2A) in contrast
to the privileged feeding site in unimmunized mice (e.g.,
Figure 2B). According to the known dynamics of tick-borne
TBEV infection in mice, disruption of the immunomodulated
site of tick feeding prevents or limits establishment of TBEV at
the initial skin infection site, a prerequisite of successful
transmission [22]. This basis for the transmission-blocking and
protective effects of 64TRP immunizations explains the
contrasting observations with the TBEV and TickGARD
vaccines since neither of these vaccines is reported to cause
an inflammatory response following tick bite.
There is now convincing evidence that blood-feeding
arthropod vectors are more than a mere syringe in trans-
mitting vector-borne pathogens. The effect of their saliva at
the skin site of feeding provides conditions that facilitate
pathogen transmission and infection. Examples include
sandflies and leishmania [38], ticks and tick-borne viruses
and bacteria [37], mosquitoes and Cache Valley and La Crosse
viruses [12,39], blackflies and vesicular stomatitis virus [14],
mites and scrub typhus bacteria [40], mosquitoes and West
Nile virus [41], and possibly Aedes mosquitoes and avian
malaria parasites [42]. A vaccine strategy aimed at creating an
antivector cell-mediated immune response at the skin site of
transmission that interferes with pathogen transmission
offers a new approach to controlling a vast range of
important vector-borne diseases.
Materials and Methods
Immunizations. Experimental Balb/c mice were arranged into
treatment groups of at least 10 animals per group (Table 2). The
following constructs of 64TRP, the tick cement protein, were used
either singly or as cocktails: TRP5 (full-length soluble protein), TRP6
(full-length denatured protein), or TRP2 (a C-terminal truncation),
expressed in Escherichia coli as GST-fusion proteins. The constructs
were as described previously [19]. Controls were mice immunized
with recombinant GST alone or naive animals that were not
immunized. The 64TRP constructs and GST control were emulsified
in Titermaxgold adjuvant (CytRx USA, Los Angeles, California,
United States). In Trial I, 80 Balb/c mice were divided into 7
experimental groups and in Trial II, 62 mice were divided into five
groups (Table 1). Mice were immunized with only a single priming
dose (10 lg) of the 64TRP antigen (or GST control) unless otherwise
specified (Table 2). All immunizations were by subcutaneous
inoculation into the prescapular region.
Serological assays. Individual host immune responses to 64TRP
immunizations were determined at wk 2 and 4, and at wk 6 after
vaccination (i.e., pre- and postchallenge antibody titers, respectively)
by end-point dilution enzyme-linked immunosorbent assays and strip
blot assays using methods described previously [19].
TBEV-infected ticks. Ticks were obtained from a laboratory colony
of uninfected I. ricinus maintained at the Institute of Virology,
Bratislava, Slovakia. TBEV donor ticks were prepared by parenteral
inoculation of I. ricinus females with 0.002 ml/tick TBEV (Hypr strain),
diluted 101. Each tick received a dose of 5,000 plaque-forming units
(PFUs) of virus. Each animal was infested with a single infected female
tick accompanied by a single uninfected male tick to promote female
tick feeding. Virus titration was as previously described [22]. After
tick feeding, salivary glands were dissected from fed adult female ticks
and assayed for TBEV; titers ranged from 100 to .1000 PFU. Nymphs
that fed for 3 d (average feeding period) were tested for acquired
TBEV; dead and unfed ticks were discarded.
Host challenge with TBEV-infected tick. When antiserum titers to
the 64TRP constructs reached 1:4,000 to 1:16,000 (4 wk after
immunization), each mouse was challenged with a single TBEV-
infected female tick, cofed with one uninfected male and 15
uninfected nymphs in a transparent retaining chamber [22]. The
same time interval (4 wk after immunization) was used to challenge
the TBEV vaccine and TickGARD (Intervet Australia Pty. Ltd.,
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Bendigo, Australia)–immunized mice. Mice that survived tick
infestation were observed for clinical signs of encephalitis for a
period of 21 d. After this observation period, to determine whether
surviving mice had indeed been exposed to TBEV infection and
developed protective immunity, each surviving animal was inoculated
intraperitoneally (i.p.) with 1,000 PFU of TBEV (Hypr strain).
Data analysis. A Chi-squared test using binomial errors was
performed to analyse the tick TBEV transmission efficiency data
and analysis of variance with regression analysis to determine the
correlations between mouse survival and transmission blocking/virus
replication. All data from mice infested with uninfected ticks, or
where ticks were not feeding or were destroyed by their host, were
excluded from the analyses on the assumption that TBEV trans-
mission had not occurred. Further, mice that did not support virus
transmission between cofeeding ticks and did not develop protective
immunity (they succumbed to i.p. inoculation of TBEV) were also
excluded from the analyses. Although the conditions used to measure
the level of protection were probably far more stringent than an
infected tick bite, it was assumed that transmission and infection of
the host had not occurred in survivors that were susceptible to i.p.
TBEV challenge.
Histological and immunocytochemical assays. The nature of the
cutaneous local inflammatory responses at tick feeding sites was
determined by necropsy studies on skin biopsies after terminal
anaesthesia, as previously described [19]. Wax-embedded skin
sections were stained with hematoxylin and eosin or with Hema
‘‘Gurr’’ Rapid Blood Smear reagents. Phenotypes of T cell lympho-
cytes infiltrating the skin of 64TRP-immunized and control mice were
characterized using antibodies to mouse cell-surface markers CD4þ
and CD8þ by immunochemical staining using CD4þ or CD8þ
antiserum (provided by Dunn School of Pathology, Oxford Univer-
sity, Oxford, United Kingdom).
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